Broken String Biosciences has opened its ‘Catalyst Early Access Program’ to select developers of gene-edited therapies, enabling them to use the company’s proprietary platform for rapidly detecting on-target and off-target effects that can occur during gene editing.
Broken String’s INDUCE-seq is a scalable platform technology for mapping and characterizing DNA breaks. According to the company, current approaches can have PCR-induced bias and miss low-frequency unintended edits that are potentially dangerous and can have disastrous consequences for clinical programs. The INDUCE-seq platform is designed to improve on existing technologies by delivering unbiased genome-wide insights, accurately detecting double-strand DNA breaks from CRISPR and other gene editing technologies.
The on-premise Catalyst program will enable developers to detect on- and off-target edits at high resolution, in days, in their own labs. Enrollment in the program will be limited to a select group of participants.
The UK-based biotech closed a $15 million Series A investment round co-led by Illumina Ventures and Mérieux Equity Partners in 2023.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!